AN AFFILIATE OF OPK BIOTECH LLC
Hemopure® was approved in 2001 by the MCC for the treatment of adult
surgical patients who are acutely anaemic. Hemopure is indicated for
the purpose of eliminating, delaying or reducing the need for allogenic
red blood cells.
Laboratory Values Reference Guide
Information for monitoring patients after Hemopure
administration. Covers haematology, clinical monitoring, serum chemistry,
coagulation, and urinalysis.
Hemopure® has been used to treat
surgical anemia in South Africa since 2001.